Please login to the form below

Not currently logged in

Par buys Anchen in $410m deal

US-based Par Pharmaceutical is to purchase generic medicines manufacturer Anchen Pharmaceuticals

Par Pharmaceutical Companies is to acquire Anchen Pharmaceuticals, a privately owned speciality pharmaceutical company focused on developing and commercialising extended release and niche generic products, for $410m (€283.6m) in cash.

California-based Anchen has five commercialised products, 27 abbreviated new drug applications (ANDAs) on file with the US Food and Drugs Administration (FDA), five of which are believed to be first-to-file and has 26 additional products in development. Anchen also anticipates launching up to 10 niche generic products during the next two years.

Patrick G LePore, chairman, chief executive and president of Par, said: "This transaction accelerates the expansion of Par's research and development infrastructure and reinforces our strategy to provide long-term sustainable growth. Anchen has an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities."

The acquisition is subject to conditions and approvals and is expected to be complete by the end of the year.

25th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...